Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal
Subscribe Donate

Indian firm develops new vaccine to fight typhoid fever

Source: Thomson Reuters Foundation - Tue, 27 Aug 2013 10:40 GMT
hum-dis hum-wat
A boy suffering from typhoid fever, caused by polluted water, lies in a hospital bed in al-Qouniya village in Syria's Idlib region. Picture May 27, 2013, REUTERS/Muzaffar Salman
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

NEW DELHI (Thomson Reuters Foundation) - Indian pharmaceutical company Bharat Biotech says it has developed the world's first clinically proven typhoid vaccine giving long-term protection to infants and adults.

Typhoid fever causes between 250,000 and 600,000 deaths a year and makes 20 million people a year ill. Around 90 percent of typhoid deaths occur in Asia and the disease occurs mainly in children under 5, the World Health Organisation says.

It is caused by Salmonella Typhi, a highly virulent and invasive bacterium, which is transmitted through food or drink contaminated by the faeces or urine of infected people.

"Bharat Biotech’s Typbar-TCV™ (vaccine) induces 'T' cell dependent response with much higher antibody levels providing a very high rate of immunity," Bharat Biotech Chairman and Managing Director Krishna M. Ella said in a statement on Monday.

"We hope this vaccine will reach millions of people and help reduce the burden of this devastating disease in infants and children."

The Hyderabad-based company said this was the world's first clinically proven fourth generation vaccine, providing long-term protection against typhoid to adults and infants of six months and older.

It said currently available typhoid vaccines fell short in two major characteristics, namely long-term protection and protection for children below 2 years of age.

"Typhoid fever remains an important public health challenge in many countries of the world. At present fundamental prevention strategies like improved sanitation, good hygienic practices and access to clean water are still out of reach for many impoverished communities," said Christian Loucq, director-general of the International Vaccine Institute.

"One of the most cost-effective approaches to prevent infectious diseases are vaccines which are available now and could help control the disease, resulting in reduction of unnecessary suffering and adverse financial consequences."

Bharat Biotech said it had begun commercial production of the vaccine in pre-filled syringes and would produce 10 million doses a year, expandable to 50 million doses in the future, which would be available globally.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
RELATED CONTENT
Related Content
Most Popular
TOPICAL CONTENT
Topical content
LATEST SLIDESHOW

Latest slideshow

See allSee all
FEATURED JOBS
Featured jobs